Literature DB >> 23417728

Serum cystatin C and prediabetes in non-obese US adults.

Charumathi Sabanayagam1, Tien Yin Wong, Jie Xiao, Anoop Shankar.   

Abstract

Diabetes mellitus is the leading cause of end stage renal disease. Cystatin C, a marker of early renal impairment has been shown to be associated with diabetes. However, it is not clear if cystatin C is associated with prediabetes, an early stage in the hyperglycemic continuum where prevention efforts have been shown to be effective in delaying or preventing the onset of diabetes. We examined 2,033 participants from the National Health and Nutrition Examination Survey 1999-2002, aged ≥ 20 years (female 47.2 %) who were free of diabetes mellitus, chronic kidney disease and with body mass index <30 kg/m(2). Prediabetes (n = 541) was defined as a 2-h glucose concentration of 140-199 mg/dL, or a fasting glucose concentration of 110-125 mg/dL, or an A1C value of 5.7-6.4 %. Cystatin C levels were categorized into gender-specific quartiles for analysis. Elevated levels of serum cystatin C were associated with prediabetes after adjusting for potential confounders including serum total cholesterol, systolic blood pressure, body mass index and C-reactive protein. Compared to those with cystatin C in the lowest quartile, the multivariable odds ratio (95 % confidence interval) of prediabetes among those in the highest quartile was 2.08 (1.09-3.97), p for trend = 0.02. Although, this association was stronger among women and non-Hispanic whites, there was no significant interaction by sex (p = 0.1) or by race-ethnicity (p = 0.6). Our findings suggest that elevated levels of serum cystatin C are associated with prediabetes in a nationally representative sample of non-obese US adults.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417728     DOI: 10.1007/s10654-013-9781-3

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  29 in total

1.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

2.  Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients.

Authors:  Michele Mussap; Michele Dalla Vestra; Paola Fioretto; Alois Saller; Mariacristina Varagnolo; Romano Nosadini; Mario Plebani
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

3.  Cystatin C as a predictor of all-cause mortality and myocardial infarction in patients with non-ST-elevation acute coronary syndrome.

Authors:  Noora Ristiniemi; Juha Lund; Risto Tertti; Anders Christensson; Tuomo Ilva; Pekka Porela; Kari Pulkki; Kim Pettersson
Journal:  Clin Biochem       Date:  2012-02-27       Impact factor: 3.281

4.  Mild renal dysfunction as a non-traditional cardiovascular risk factor?-Association of cystatin C-based glomerular filtration rate with flow-mediated vasodilation.

Authors:  Thorsten Reffelmann; Alexander Krebs; Till Ittermann; Klaus Empen; Astrid Hummel; Marcus Dörr; Henry Völzke; Stephan B Felix
Journal:  Atherosclerosis       Date:  2010-03-27       Impact factor: 5.162

Review 5.  Update on cystatin C: new insights into the importance of mild kidney dysfunction.

Authors:  Michael G Shlipak; Melanie L Praught; Mark J Sarnak
Journal:  Curr Opin Nephrol Hypertens       Date:  2006-05       Impact factor: 2.894

6.  Serum cystatin C and the incidence of type 2 diabetes mellitus.

Authors:  K Sahakyan; K E Lee; A Shankar; R Klein
Journal:  Diabetologia       Date:  2011-03-05       Impact factor: 10.122

7.  Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases.

Authors:  J Leung-Tack; C Tavera; J Martinez; A Colle
Journal:  Inflammation       Date:  1990-06       Impact factor: 4.092

8.  Relationship between body mass index and high cystatin levels among US adults.

Authors:  Anoop Shankar; Srinivas Teppala
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-11-07       Impact factor: 3.738

9.  Cystatin C as an early biomarker of nephropathy in patients with type 2 diabetes.

Authors:  Yun Kyung Jeon; Mi Ra Kim; Jung Eun Huh; Ji Young Mok; Sang Heon Song; Sang Soo Kim; Bo Hyun Kim; Soo Hyoung Lee; Yong Ki Kim; In Joo Kim
Journal:  J Korean Med Sci       Date:  2011-01-24       Impact factor: 2.153

10.  Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.

Authors:  Catherine C Cowie; Keith F Rust; Earl S Ford; Mark S Eberhardt; Danita D Byrd-Holt; Chaoyang Li; Desmond E Williams; Edward W Gregg; Kathleen E Bainbridge; Sharon H Saydah; Linda S Geiss
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

View more
  12 in total

1.  The Rotterdam Study: 2016 objectives and design update.

Authors:  Albert Hofman; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; M Arfan Ikram; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Ch Stricker; Henning W Tiemeier; André G Uitterlinden; Meike W Vernooij
Journal:  Eur J Epidemiol       Date:  2015-09-19       Impact factor: 8.082

2.  High cystatin C levels predict severe retinopathy in type 2 diabetes patients.

Authors:  Rui He; Jing Shen; Jun Zhao; Hui Zeng; Lianxi Li; Jungong Zhao; Fang Liu; Weiping Jia
Journal:  Eur J Epidemiol       Date:  2013-08-06       Impact factor: 8.082

3.  Cystatin C as a Predictor for Diabetes according to Glycosylated Hemoglobin Levels in Korean Patients.

Authors:  Eon Ju Jeon; Ji Hyun Lee
Journal:  Diabetes Metab J       Date:  2016-02       Impact factor: 5.376

4.  The Generation R Study: Biobank update 2015.

Authors:  Claudia J Kruithof; Marjolein N Kooijman; Cornelia M van Duijn; Oscar H Franco; Johan C de Jongste; Caroline C W Klaver; Johan P Mackenbach; Henriëtte A Moll; Hein Raat; Edmond H H M Rings; Fernando Rivadeneira; Eric A P Steegers; Henning Tiemeier; Andre G Uitterlinden; Frank C Verhulst; Eppo B Wolvius; Albert Hofman; Vincent W V Jaddoe
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

Review 5.  Early origins of chronic obstructive lung diseases across the life course.

Authors:  Liesbeth Duijts; Irwin K Reiss; Guy Brusselle; Johan C de Jongste
Journal:  Eur J Epidemiol       Date:  2014-12-24       Impact factor: 8.082

6.  Body mass index and preclinical kidney disease in Indian adults aged 40 years and above without chronic kidney disease.

Authors:  Charumathi Sabanayagam; Tien Yin Wong; Jiemin Liao; Sunil Sethi; Boon Wee Teo
Journal:  Clin Exp Nephrol       Date:  2014-02-14       Impact factor: 2.801

7.  Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease.

Authors:  Mariëtte E G Kranendonk; Dominique P V de Kleijn; Eric Kalkhoven; Danny A Kanhai; Cuno S P M Uiterwaal; Yolanda van der Graaf; Gerard Pasterkamp; Frank L J Visseren
Journal:  Cardiovasc Diabetol       Date:  2014-02-05       Impact factor: 9.951

8.  Letter: The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults (Diabetes Metab J 2016;40:62-9).

Authors:  Kyung Soo Kim
Journal:  Diabetes Metab J       Date:  2016-04       Impact factor: 5.376

9.  The Association of Serum Cystatin C with Glycosylated Hemoglobin in Korean Adults.

Authors:  Eun Hee Sim; Hye Won Lee; Hyun Ju Choi; Dong Wook Jeong; Seok Man Son; Yang Ho Kang
Journal:  Diabetes Metab J       Date:  2016-02       Impact factor: 5.376

10.  Relationship between High Serum Cystatin C Levels and the Risk of Gestational Diabetes Mellitus.

Authors:  Weijing Zhao; Jiemin Pan; Huaping Li; Yajuan Huang; Fang Liu; Minfang Tao; Weiping Jia
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.